<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Smallpox and mpox (monkeypox) vaccine (live, nonreplicating) (United States: Availability limited to health department/Strategic National Stockpile distribution): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Smallpox and mpox (monkeypox) vaccine (live, nonreplicating) (United States: Availability limited to health department/Strategic National Stockpile distribution): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Smallpox and mpox (monkeypox) vaccine (live, nonreplicating) (United States: Availability limited to health department/Strategic National Stockpile distribution): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="122670" href="/d/html/122670.html" rel="external">see "Smallpox and mpox (monkeypox) vaccine (live, nonreplicating) (United States: Availability limited to health department/Strategic National Stockpile distribution): Drug information"</a> and <a class="drug drug_patient" data-topicid="122738" href="/d/html/122738.html" rel="external">see "Smallpox and mpox (monkeypox) vaccine (live, nonreplicating) (United States: Availability limited to health department/Strategic National Stockpile distribution): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56943452"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Jynneos</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57271095"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Imvamune</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F57134420"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Vaccine</span>;</li>
<li>
<span class="list-set-name">Vaccine, Live (Viral)</span></li></ul></div>
<div class="block dop drugH1Div" id="F57131663"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Safety and effectiveness have not been assessed in ages &lt;18 years; emergency use authorization is based on adult data and historical use of live vaccinia virus smallpox vaccine in pediatric populations.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="937db9e2-a48f-4ad7-9c9f-6b65d8ae8b3e">Primary immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary immunization:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Jynneos:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Primary vaccination</i>: <b>Note:</b> Authorized route of administration varies based on age; use caution when ordering and administering. For patients &lt;18 years of age, only SUBQ administration is authorized. For patients ≥18 years of age, intradermal administration is preferred in the United States for the current 2022 outbreak to extend vaccine supply. For persons with a history of keloid scars, SUBQ administration is recommended regardless of age (CDC 2022c). For postexposure prophylaxis, administration within 4 days of exposure is the most effective. If given 4 to 14 days after exposure, the vaccine may reduce symptoms but not prevent disease (CDC 2022a).</p>
<p style="text-indent:-2em;margin-left:8em;">SUBQ:</p>
<p style="text-indent:-2em;margin-left:10em;">Infants, Children, and Adolescents: SUBQ: 0.5 mL per dose given as 2 doses separated by 4 weeks (FDA 2022; manufacturer's labeling). <b>Note:</b> In individuals ≥18 years, the second dose may be administered intradermally if necessary (CDC 2022c).</p>
<p style="text-indent:-2em;margin-left:8em;">Intradermal:</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents ≥18 years: Intradermal: 0.1 mL per dose given as 2 doses separated by 4 weeks (FDA 2022; Frey 2015).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Booster dose</i>: Limited data available: Adolescents ≥18 years: SUBQ: 0.5 mL every 2 years for persons at continued risk of exposure for more virulent strains (eg, variola virus, monkeypox virus) or at least every 10 years for less virulent strains (eg, vaccinia virus, cowpox virus) (CDC/ACIP [Rao 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">Imvamune (Canadian product): <b>Note:</b> Canadian product administration is SUBQ for all approved ages.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Primary vaccination:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Preexposure prophylaxis: Adolescents ≥18 years: SUBQ: 0.5 mL per dose given as 2 doses separated by 4 weeks (NACI 2022).</p>
<p style="text-indent:-2em;margin-left:8em;">Postexposure prophylaxis: Adolescents ≥18 years: SUBQ: 0.5 mL as a single dose. If risk of exposure continues, may consider a second 0.5 mL dose after 28 days. <b>Note:</b> Administer as soon as possible and within 4 days of exposure; may consider use up to 14 days after exposure (NACI 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Booster dose:</i> Adolescents ≥18 years: SUBQ: 0.5 mL every 2 years if the person remains at increased risk of exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Interchangeability:</b> Jynneos or Imvamune may be used as a booster dose (as age-appropriate) for those persons who received a primary series with the smallpox vaccine (ACAM2000) and who are at continued risk for exposure (CDC/ACIP [Rao 2022]; NACI 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing recommendations for deviations in dosage or storage:</b></p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Recommendations for Deviations in Smallpox and Monkeypox Vaccine Usage<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Deviation</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Adjustment</b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<sup>a </sup>CDC 2022a.</p>
<p style="text-indent:0em;">
<sup>b</sup> Dose administered up to 4 days before the minimum interval is considered a valid dose; do not repeat.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<i>
<b>Dose</b></i></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Dose too high</p></td>
<td align="left">
<p style="text-indent:0em;">Do not repeat dose. Counsel recipient regarding adverse event potential.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Dose too low – Intradermal (eg, injection site leakage, syringe leakage)</p></td>
<td align="left">
<p style="text-indent:0em;">Repeat dose immediately (no minimum interval); administer ≥2 inches away from the previous site of administration.</p>
<p style="text-indent:0em;margin-top:2em;">If vaccine leakage after 2 intradermal injections on same day, then administer 0.5 mL SUBQ.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Dose too low – SUBQ (eg, 0.1 mL dose given SUBQ when intradermal route intended, syringe leakage)</p></td>
<td align="left">
<p style="text-indent:0em;">Repeat dose immediately with the correct dose (no minimum interval); administer ≥2 inches away from the previous site of administration.</p>
<p style="text-indent:0em;margin-top:2em;">Alternatively, if a partial dose was administered, may administer the remainder of the dose (on the same clinic day) to equal a full dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Half-dose volume administered inadvertently</p></td>
<td align="left">
<p style="text-indent:0em;">If same clinic day, administer another half dose (2 doses counted as full dose). If different day, repeat dose.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<i>
<b>Dosing interval</b></i></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Dose administered too early (ie, more than 4 days prior to the recommended interval)<sup>b</sup></p></td>
<td align="left">
<p style="text-indent:0em;">For patients who are not immunocompromised, do not repeat dose. For patients who are severely immunocompromised, administer a repeat dose ≥28 days from dose given in error.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Dose administered after recommended interval</p></td>
<td align="left">
<p style="text-indent:0em;">Do not repeat dose or restart the series; no maximum interval. Give second dose as soon as possible.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;">
<i>
<b>Storage</b></i></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Improper storage or handling of vaccine (eg, temperature excursion, dose administered past expiration date)</p></td>
<td align="left">
<p style="text-indent:0em;">Contact manufacturer; if no stability data, repeat dose immediately (no minimum interval).</p></td></tr></tbody></table></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F57131664"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F57131665"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F53823798"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="122670" href="/d/html/122670.html" rel="external">see "Smallpox and mpox (monkeypox) vaccine (live, nonreplicating) (United States: Availability limited to health department/Strategic National Stockpile distribution): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="937db9e2-a48f-4ad7-9c9f-6b65d8ae8b3e">Primary immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary immunization:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Jynneos</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Primary vaccination: <b>Note:</b> Intradermal administration is preferred in the United States for the current outbreak to extend vaccine supply; SUBQ administration is recommended for persons with a history of keloid scars. Routes of administration are interchangeable if necessary (eg, if first dose administered as 0.5 mL SUBQ, then second dose may be administered as either 0.5 mL SUBQ or 0.1 mL intradermally) (CDC 2022c). For postexposure prophylaxis, administration within 4 days of exposure is the most effective. If given 4 to 14 days after exposure, the vaccine may reduce symptoms but not prevent disease (CDC 2022a).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Intradermal:</b> 0.1 mL per dose given as 2 doses separated by 4 weeks (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>SUBQ:</b> 0.5 mL per dose given as 2 doses separated by 4 weeks (CDC/ACIP [Rao 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">Booster dose (off-label): <b>SUBQ:</b> 0.5 mL every 2 years for persons at continued risk of exposure for more virulent strains (eg, <i>Variola virus,</i>
<i>Monkeypox virus) </i>or at least every 10 years for less virulent strains (eg, <i>Vaccinia virus</i>, <i>Cowpox virus</i>) (CDC/ACIP [Rao 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Imvamune (Canadian product):</b></p>
<p style="text-indent:-2em;margin-left:6em;">Primary vaccination:</p>
<p style="text-indent:-2em;margin-left:8em;">Preexposure prophylaxis: <b>SUBQ:</b> 0.5 mL per dose given as 2 doses separated by 4 weeks (NACI 2022)</p>
<p style="text-indent:-2em;margin-left:8em;">Postexposure prophylaxis: <b>SUBQ</b>: 0.5 mL as a single dose. If risk of exposure continues, may consider a second 0.5 mL dose after 28 days. <b>Note: </b>Administer as soon as possible and within 4 days of exposure; may consider use up to 14 days after exposure (NACI 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">Booster dose: <b>SUBQ: </b>0.5 mL every 2 years if the person remains at increased risk of exposure.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Interchangeability:</b> Jynneos or Imvamune may be used as a booster dose for those persons who received a primary series with the smallpox vaccine (ACAM2000) and who are at continued risk for exposure (CDC/ACIP [Rao 2022]; NACI 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing recommendations for deviations in dosage or storage:</b></p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Recommendations for Deviations in Smallpox and Monkeypox Vaccine Usage</b>
<b>
<sup>a,b</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Deviation</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Adjustment</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> CDC 2022a.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> Dose administered up to 4 days before the minimum interval is considered a valid dose; do not repeat.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<i>
<b>Dose</b></i></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose too high</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Do not repeat dose. Counsel recipient regarding adverse event potential.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Dose too low – Intradermal (eg, injection-site leakage, syringe leakage)</p></td>
<td align="left">
<p style="text-indent:0em;">Repeat dose immediately (no minimum interval); administer ≥2 inches away from the previous site of administration.</p>
<p style="text-indent:0em;">If vaccine leakage after 2 intradermal injections on same day, then administer 0.5 mL SUBQ.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose too low – SUBQ (eg, 0.1 mL dose given SUBQ when intradermal route intended, syringe leakage)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Repeat dose immediately with the correct dose and intended route of administration (no minimum interval); administer ≥2 inches away from the previous site of administration.</p>
<p style="text-indent:0em;text-align:left;">Alternatively, if a partial dose was administered, may administer the remainder of the dose (on the same clinic day) to equal a full dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Half-dose volume administered inadvertently</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If same clinic day, administer another half dose (2 doses counted as full dose). If different day, repeat dose.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<i>
<b>Dosing interval</b></i></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose administered too early (ie, more than 4 days prior to the recommended interval)<sup>b</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">For patients who are not immunocompromised, do not repeat dose. For patients who are severely immunocompromised, administer a repeat dose ≥28 days from dose given in error.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dose administered after recommended interval</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Do not repeat dose or restart the series; no maximum interval. Give second dose as soon as possible.</p></td></tr>
<tr>
<td align="left" colspan="2">
<p style="text-indent:0em;text-align:left;">
<i>
<b>Storage</b></i></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Improper storage or handling of vaccine (eg, temperature excursion, dose administered past expiration date)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Contact manufacturer; if no stability data, repeat dose immediately (no minimum interval).</p></td></tr></tbody></table></div>
</div>
</div>
<div class="block dora drugH1Div" id="F53823800"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F53823801"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F57197094"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular effects, including <b>ECG abnormality</b> (<b>abnormal T waves on ECG</b>, <b>increased ST segment on ECG</b>, <b>inversion T wave on ECG</b>), <b>myocarditis</b>, <b>palpitations</b>, <b>pericarditis</b>, and <b>tachycardia</b> have been reported with smallpox and monkeypox vaccination. Asymptomatic troponin increases ≤2 times ULN have also been reported; the clinical significance is unclear.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F53696629"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse reactions and incidences are derived from product labeling and the FDA issued emergency use authorization (EUA) unless otherwise specified. Refer to EUA for information regarding reporting adverse reactions (FDA 2022). Adverse reactions reported in adults for SUBQ and intradermal routes of administration, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Change in appetite (15% to 20%), nausea (10% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (SUBQ: 61% to 81%; intradermal: 100%), induration at injection site (SUBQ: 45% to 70%; intradermal: 100%), injection-site pruritus (SUBQ: 32% to 49%; intradermal: 89%), local swelling (underarm: 6% to 11%), pain at injection site (SUBQ: 80% to 91%; intradermal: 65%), swelling at injection site (SUBQ: 52% to 67%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (≤15%), fatigue (30% to 51%), headache (28% to 43%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arm and/or wrist pain (underarm pain: 18% to 21%), arthralgia (9% to 18%), myalgia (22% to 43%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac disorder (SUBQ: 1% to 2%; including ECG abnormality [abnormal T waves on ECG, increased ST segment on ECG, inversion T wave on ECG], palpitations, tachycardia, troponin increased in blood specimen)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (SUBQ: ≤2%)</p>
<p style="text-indent:-4em;margin-left:4em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Myocarditis, pericarditis, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reactions (including angioedema)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized vesiculation (injection site), warm sensation at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness</p></div>
<div class="block coi drugH1Div" id="F53685261"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Serious hypersensitivity to any component of the formulation (CDC/ACIP [Rao 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Acute febrile illness if used for nonemergency (preexposure) prophylaxis.</p></div>
<div class="block war drugH1Div" id="F53823793"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the Advisory Committee on Immunization Practices (ACIP) generally recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or nonlive) for which a person is eligible at a single clinic visit, unless contraindications exist. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible (ACIP [Kroger 2023]). Because of the potential risk for myocarditis related to the mRNA COVID-19 vaccine and the unknown risk related to Jynneos or Imvamune, consider separating the orthopoxvirus vaccine by 4 weeks from the mRNA COVID-19 vaccine (especially for adolescent/young adult males). However, separation of vaccines is not recommended during an orthopoxvirus outbreak (CDC/ACIP [Rao 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: The vaccine has been shown to be safe to administer in persons with an immunocompromising condition if no contraindications exist. Immunocompromised persons may have a diminished immune response to the vaccine; consider risk:benefit ratio (CDC/ACIP [Rao 2022]). For management of postexposure to smallpox virus, vaccination with the live, nonreplicating vaccine (eg, Jynneos) is recommended in patients who are severely immunodeficient (including HIV infection with CD4 cell counts between 50 to 199 cells/mm<sup>3</sup>)(CDC/ACIP [Petersen 2015]). However, for routine immunization in applicable individuals, consider postponing vaccination during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]) if appropriate; may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines (ACIP [Kroger 2023]; IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Chicken egg protein: Jynneos is produced using chicken embryo fibroblast cells; use with caution in patients with a history of severe allergic reaction to chicken or egg protein <b>and</b> who are currently avoiding exposure to all chicken or egg products (CDC 2022c).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ciprofloxacin: Manufactured with ciprofloxacin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gentamicin: Manufactured with gentamicin.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Antipyretics: Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2023]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (ACIP [Kroger 2023]).</p></div>
<div class="block foc drugH1Div" id="F56943453"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jynneos: 0.5 mL (0.5 mL) [contains serratia marcescens nuclease (benzonase)]</p></div>
<div class="block geq drugH1Div" id="F56943451"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57055656"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Jynneos Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mL (per 0.5 mL): $0.01</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57271096"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension, Subcutaneous:</p>
<p style="text-indent:-2em;margin-left:4em;">Imvamune: 0.5 mL (0.5 mL) [contains benzonase]</p></div>
<div class="block accres drugH1Div" id="F53823789"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Jynneos is part of the US federal government’s Strategic National Stockpile. Additional information is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Femergency-preparedness-and-response%2Fmcm-issues%2Fsmallpox-preparedness-and-response-updates-fda&amp;token=8CLjuLVtoKzpw11L8e6Vl4r8VO6PW1HhDjvHklB4Nw25MWP9MTX4LE3%2BYz87d852%2Br0x4uPaBlfrUCXa9AlI6xzmb3eFaiwzaWdD6Idaa95vytt3U5AFBJ6m4q2cJc22&amp;TOPIC_ID=139403" target="_blank">https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/smallpox-preparedness-and-response-updates-fda</a> and <a href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fpoxvirus%2Fmonkeypox%2Fconsiderations-for-monkeypox-vaccination.html&amp;token=BL9eT1VFk36OwjnSXjPADvZaJHNMiERFRYessm2hpLpn0ZblHZh9OdRwQv4LPjVbM9pNot7%2Fw0YdowJyD3djLKcakSiVTYuRvBBSMOqrDhM%3D&amp;TOPIC_ID=139403" target="_blank">https://www.cdc.gov/poxvirus/monkeypox/considerations-for-monkeypox-vaccination.html</a>.</p></div>
<div class="block admp drugH1Div" id="F57131666"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Swirl vial gently for ≥30 seconds before each use. In pediatric patients, authorized route of administration varies based on age (SUBQ vs intradermal); use caution. Do not administer IM or intravascularly</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: Inject preferably over the anterolateral thigh (CDC 2022c; FDA 2022).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: Inject preferably into the upper arm (typically over the triceps area) (CDC 2022c; FDA 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">Intradermal: Adolescents ≥18 years: Inject preferably into the inner side of the forearm. Alternatively, may administer in the upper back (below the scapula) or deltoid area. After administration, formation of a wheal is desired but not required (CDC 2022c). Extract doses from vial preferably using a low dead-volume syringe and/or needle. If standard syringes and needles are used, there may not be sufficient volume for all stated doses. Do not pool partial doses remaining in vials into a full dose (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope-related injuries, patients should be vaccinated while seated or lying down (ACIP [Kroger 2023]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement edition date and date it was provided, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>
<p style="text-indent:-2em;margin-left:2em;">Inappropriate administration technique:</p>
<p style="text-indent:-2em;margin-left:4em;">If administered into an incorrect site, do not repeat dose (CDC 2022a).</p>
<p style="text-indent:-2em;margin-left:4em;">If incorrect route of administration resulting in a lower than intended dosage (eg, SUBQ administration of the intradermal dose of 0.1 mL), then immediately repeat dose using the intended route of administration (≥2 inches away from the unintended site placement). If other incorrect route (eg, IM administration), do not repeat dose (CDC 2022a).</p></div>
<div class="block adm drugH1Div" id="F53823802"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Swirl vial gently for ≥30 seconds before each use. Do not administer IM or intravascularly.</p>
<p style="text-indent:-2em;margin-left:2em;">Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope-related injuries, patients should be vaccinated while seated or lying down (ACIP [Kroger 2023]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement edition date and date it was provided, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intradermal:</b> Inject preferably into the inner side of the forearm. Alternatively, may administer in the upper back (below the scapula) or deltoid area. After administration, formation of a wheal is desired but not required (CDC 2022c). Extract doses from vial preferably using a low dead-volume syringe and/or needle. If standard syringes and needles are used, there may not be sufficient volume for all stated doses. Do not pool partial doses remaining in vials into a full dose (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ: </b>Inject preferably into the upper arm (typically over the triceps area) (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Inappropriate administration technique:</b></p>
<p style="text-indent:-2em;margin-left:4em;">If administered into an incorrect site, do not repeat dose (CDC 2022a).</p>
<p style="text-indent:-2em;margin-left:4em;">If incorrect route of administration results in a lower than intended dosage (eg, SUBQ administration of the intradermal dose of 0.1 mL), then immediately repeat dose using the intended route of administration (≥2 inches away from the unintended site placement). If other incorrect route (eg, IM administration), do not repeat dose (CDC 2022a).</p></div>
<div class="block sts drugH1Div" id="F53823795"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>For information related to improper storage or handling of vaccine (eg, temperature excursion, dose administered past expiration date), contact manufacturer.</p>
<p style="text-indent:-2em;margin-left:2em;">Store intact vials frozen at −25°C to −15°C (−13°F to 5°F) and in the original package to protect from light. Under the Emergency Use Authorization, once thawed, the vaccine is stable for 8 weeks when stored at 2°C to 8°C (36°F to 46°F); in-use vials (after first puncture) may be stored for up to 8 hours at 2°C to 8°C (36°F to 46°F); do not refreeze (FDA EUA August 2022). <b>Note:</b> The manufacturer's labeling states that once thawed, the vaccine is stable for 4 weeks when stored at 2°C to 8°C (36°F to 46°F); do not refreeze (Jynneos Prescribing Information March 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">Imvamune vaccine (Canadian product): Store intact vial frozen at −90°C to −15°C (−130°F to 5°F). May also be stored refrigerated at 2°C to 8°C (36°F to 46°F) for up to 2 months. After thawing, the vaccine is stable for 2 months when refrigerated at 2°C to 8°C (36°F to 46°F). Do not refreeze. Store in original packaging to protect from light. Additional storage information is available at <a href="/external-redirect?target_url=https%3A%2F%2Frecalls-rappels.canada.ca%2Fen%2Falert-recall%2Fimvamune-vaccine-updated-storage-conditions-and-shelf-life&amp;token=6pwUYdh%2FY%2FCEPLBf866GEzif7Dp3Pndm4%2F07B2PWmbbk%2BmIagPPbgB8R%2BFxoowJQC16syfPTKz0UDcnKSaBSO9KzfJMzbI0hTunntWKQvByBDeN%2FN2zLCpXbEmtz9%2FEh&amp;TOPIC_ID=139403" target="_blank">https://recalls-rappels.canada.ca/en/alert-recall/imvamune-vaccine-updated-storage-conditions-and-shelf-life</a>.</p></div>
<div class="block usep drugH1Div" id="F57131648"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Prevention of smallpox and mpox (monkeypox) disease in patients determined to be at high risk for smallpox or monkeypox virus infection (FDA approved in ages ≥18 years and adults; FDA issued emergency use authorization for mpox [monkeypox] prevention in ages &lt;18 years) (FDA 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<i>Preexposure prophylaxis:</i></p>
<p style="text-indent:-2em;margin-left:6em;">The Advisory Committee on Immunization Practices recommends vaccination for the following adults at risk for occupational exposure to orthopoxviruses (CDC/ACIP [Rao 2022]):</p>
<p style="text-indent:-2em;margin-left:8em;">• Research laboratory personnel working with orthopoxviruses.</p>
<p style="text-indent:-2em;margin-left:8em;">• Clinical laboratory personnel performing diagnostic testing for orthopoxviruses.</p>
<p style="text-indent:-2em;margin-left:8em;">• Designated public health and health care worker response team members.</p>
<p style="text-indent:-2em;margin-left:8em;">• Health care personnel who administer the live smallpox vaccine (ACAM2000) or who care for patients infected with orthopoxviruses (eg, monkeypox virus) (per shared clinical decision making).</p>
<p style="text-indent:-2em;margin-left:6em;">The Canadian National Advisory Committee on Immunization (NACI) recommends vaccination for adults at high risk for occupational exposure to orthopoxviruses in a laboratory setting. In addition, NACI also makes recommendations on populations who may be offered vaccination based on monkeypox virus exposure risk; see recommendations for details (NACI 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis:</i> The CDC and NACI recommend vaccination as postexposure prophylaxis following exposure or possible exposure to monkeypox virus; see current public health updates for recommendations and details (CDC 2022a; NACI 2022).</p></div>
<div class="block cyt drugH1Div" id="F53710786"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F53710783"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation or 6 months after anti-CD20 B-cell depleting therapies. If vaccinated prior to B cell recovery, consider assessing immune response to vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: May diminish the therapeutic effect of Smallpox and Monkeypox Vaccine (Live).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of cladribine when possible. Patients vaccinated less than 14 days before initiating or during cladribine should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Smallpox and Monkeypox Vaccine (Live) may enhance the adverse/toxic effect of COVID-19 Vaccine (mRNA). Specifically, the risk of myocarditis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 3 after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Administer vaccines at least 2 weeks prior to methotrexate initiation, if possible. If patients are vaccinated less than 14 days prior to or during methotrexate therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Avoid administration of vaccines (inactivated) during treatment with siponimod and for 1 month after discontinuation due to potential decreased vaccine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating). Management: Vaccination with inactivated or non-replicating vaccines is not recommended in the 2 weeks prior to teplizumab therapy, during treatment, or for 6 weeks following completion of therapy.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F53823791"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following maternal exposure to this vaccine is limited (Volkmann 2021). However, maternal smallpox or mpox (monkeypox) is associated with adverse maternal and fetal outcomes (Mbala 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Infection with the monkeypox virus may lead to adverse pregnancy outcomes, including spontaneous pregnancy loss, stillbirth, and transmission of the monkeypox virus to the fetus or newborn. When a pregnant patient is diagnosed with mpox (monkeypox), neonatal health care providers should be informed of the diagnosis (CDC 2022b; Mbala 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Smallpox infection during pregnancy increases the risk of severe maternal disease (including hemorrhagic smallpox) and death; the fatality rate in unvaccinated pregnant patients can be up to 70%. Pregnant health care workers should avoid direct patient care during an initial emergency response to a smallpox outbreak (CDC [Petersen 2015]).</p>
<p style="text-indent:0em;margin-top:2em;">Pregnancy is not a specific contraindication for vaccination (CDC/ACIP [Rao 2022]). The smallpox and monkeypox vaccine is a nonreplicating live viral vaccine; pregnant patients who otherwise meet the criteria for monkeypox vaccination can be vaccinated following a discussion of the risks and benefits of pre- or postexposure prophylaxis (CDC 2022b). Following vaccination, patients should continue to avoid conditions with high-risk exposure while pregnant (CDC/ACIP [Rao 2022]).</p></div>
<div class="block mopp drugH1Div" id="F57131667"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2023]). Observe for 30 minutes after vaccination; patients with a history of severe allergic reaction to gentamicin, ciprofloxacin, or to chicken or egg protein (and are currently avoiding exposure to all chicken or egg products) (CDC 2022c). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion (ACIP [Kroger 2022]).</p></div>
<div class="block pha drugH1Div" id="F53823797"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Vaccination elicits humoral and cellular immune responses to orthopoxviruses. Smallpox and monkeypox vaccine is a live, third-generation smallpox vaccine containing Modified Vaccinia Ankara, which is replication deficient and cannot cause disease in humans or reproduce in human cells.</p></div>
<div class="block phk drugH1Div" id="F57009476"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Onset of action: Peak antibody response for Jynneos is typically achieved 2 weeks after completion of the 2-dose series (CDC/ACIP [Rao 2022]).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58215834"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Imvanex</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Jynneos</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Imvanex | Jynneos</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Imvanex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Imvanex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Jynneos</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16456528">
<a name="16456528"></a>Casey C, Vellozzi C, Mootrey GT, et al. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. Centers for Disease Control and Prevention. Published February 3, 2006. Accessed August 22, 2022. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5501a1.htm" target="_blank">https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5501a1.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/smallpox-and-mpox-monkeypox-vaccine-live-nonreplicating-united-states-availability-limited-to-health-department-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/16456528/pubmed" id="16456528" target="_blank">16456528</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Clinical considerations for monkeypox in people who are pregnant or breastfeeding. Updated July 18, 2022b. Accessed July 28, 2022. <a href="https://www.cdc.gov/poxvirus/monkeypox/clinicians/pregnancy.html" target="_blank">https://www.cdc.gov/poxvirus/monkeypox/clinicians/pregnancy.html</a>.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Interim clinical considerations for use of JYNNEOS and ACAM2000 vaccines during the 2022 U.S. monkeypox outbreak. Updated August 22, 2022a. Accessed August 31, 2022. <a href="https://www.cdc.gov/poxvirus/monkeypox/health-departments/vaccine-considerations.html" target="_blank">https://www.cdc.gov/poxvirus/monkeypox/health-departments/vaccine-considerations.html</a>.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Jynneos vaccine. Updated September 28, 2022c. Accessed October 6, 2022. <a href="https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/jynneos-vaccine.html" target="_blank">https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/jynneos-vaccine.html</a>.</div>
</li>
<li>
<div class="reference">
                  Imvamune (smallpox and monkeypox vaccine [live-attenuated, non-replicating]) [product monograph]. Newmarket, Ontario, Canada: Progress Therapeutics Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26143613">
<a name="26143613"></a>Frey SE, Wald A, Edupuganti S, et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. <i>Vaccine</i>. 2015;33(39):5225-5234. doi:10.1016/j.vaccine.2015.06.075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/smallpox-and-mpox-monkeypox-vaccine-live-nonreplicating-united-states-availability-limited-to-health-department-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/26143613/pubmed" id="26143613" target="_blank">26143613</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Jynneos (smallpox and monkeypox vaccine [live]) [prescribing information]. Kvistgaard, Denmark: Bavarian Nordic A/S; March 2023.</div>
</li>
<li>
<div class="reference">
                  Jynneos (smallpox and monkeypox vaccine [live]) [prescribing information]. Hellerup, Denmark: Bavarian Nordic A/S; September 2023.</div>
</li>
<li>
<div class="reference">
                  Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</a>. Accessed May 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29029147">
<a name="29029147"></a>Mbala PK, Huggins JW, Riu-Rovira T, et al. Maternal and fetal outcomes among pregnant women with human monkeypox infection in the Democratic Republic of Congo. <i>J Infect Dis</i>. 2017;216(7):824-828. doi:10.1093/infdis/jix260.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/smallpox-and-mpox-monkeypox-vaccine-live-nonreplicating-united-states-availability-limited-to-health-department-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/29029147/pubmed" id="29029147" target="_blank">29029147</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Advisory Committee on Immunization (NACI). NACI rapid response - interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada. Published June 10, 2022. Accessed July 7, 2022. <a href="https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-imvamune-monkeypox.html" target="_blank">https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/guidance-imvamune-monkeypox.html</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25695372">
<a name="25695372"></a>Petersen BW, Damon IK, Pertowski CA, et al. Clinical guidance for smallpox vaccine use in a postevent vaccination program. <i>MMWR Recomm Rep</i>. 2015;64(RR-2):1-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/smallpox-and-mpox-monkeypox-vaccine-live-nonreplicating-united-states-availability-limited-to-health-department-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/25695372/pubmed" id="25695372" target="_blank">25695372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26985679">
<a name="26985679"></a>Petersen BW, Harms TJ, Reynolds MG, Harrison LH. Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses - recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015. <i>MMWR Morb Mortal Wkly Rep</i>. 2016;65(10):257-262. doi:10.15585/mmwr.mm6510a2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/smallpox-and-mpox-monkeypox-vaccine-live-nonreplicating-united-states-availability-limited-to-health-department-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/26985679/pubmed" id="26985679" target="_blank">26985679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35653347">
<a name="35653347"></a>Rao AK, Petersen BW, Whitehill F, et al. Use of JYNNEOS (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: recommendations of the Advisory Committee on Immunization Practices - United States, 2022. <i>MMWR Morb Mortal Wkly Rep.</i> 2022;71(22):734-742. doi:10.15585/mmwr.mm7122e1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/smallpox-and-mpox-monkeypox-vaccine-live-nonreplicating-united-states-availability-limited-to-health-department-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/35653347/pubmed" id="35653347" target="_blank">35653347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host [published correction appears in <i>Clin Infect Dis</i>. 2014;59(1):144]. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100. doi:10.1093/cid/cit684.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/smallpox-and-mpox-monkeypox-vaccine-live-nonreplicating-united-states-availability-limited-to-health-department-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). Fact sheet for healthcare providers administering vaccine: Emergency Use Authorization (EUA) of Jynneos (smallpox and monkeypox vaccine, live, non-replicating) for prevention of monkeypox disease in individuals determined to be at high risk for monkeypox infection. Updated August 16, 2022. Accessed August 23, 2022. <a href="https://www.fda.gov/media/159312/download" target="_blank">https://www.fda.gov/media/159312/download</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33077299">
<a name="33077299"></a>Volkmann A, Williamson AL, Weidenthaler H, et al; Brighton Collaboration Viral Vector Vaccines Safety Working Group V3SWG. The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform. <i>Vaccine</i>. 2021;39(22):3067-3080. doi:10.1016/j.vaccine.2020.08.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/smallpox-and-mpox-monkeypox-vaccine-live-nonreplicating-united-states-availability-limited-to-health-department-strategic-national-stockpile-distribution-pediatric-drug-information/abstract-text/33077299/pubmed" id="33077299" target="_blank">33077299</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 139403 Version 37.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
